

Consolidated Financial Results for the Second Quarter of FY2019

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2018 Apr. 2018-Sep. 2018		FY2019 Apr. 2019-Sep. 2019		YoY
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	23,477	100.0%	26,582	100.0%	13.2%
Cost of Sales	14,026	59.7%	14,492	54.5%	3.3%
Gross Profit	9,450	40.3%	12,089	45.5%	27.9%
Selling, General and Administrative Expenses	8,486	36.1%	11,343	42.7%	33.7%
Operating Income	960	4.1%	746	2.8%	-22.3%
Profit Attributable to Owners of Parent	743	3.2%	577	2.2%	-22.3%

Forecast of Consolidated Financial Results for the FY2019

	FY2018 Actual Apr. 2018-Mar. 2019		FY2019 Forecast Apr. 2019-Mar. 2020		YoY
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	46,706	100.0%	53,000	100.0%	13.5%
Operating Income	1,782	3.8%	2,000	3.8%	12.2%
Profit Attributable to Owners of Parent	1,744	3.7%	1,000	1.9%	-42.7%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2018 Q2 Actual	FY2019 Q2 Actual	FY2019 Forecast
Antihypertensive agent	CANDESARTAN*	6.08	6.88	13.60
Thyroid hormone	THYRADIN	3.01	3.43	6.98
LH-RH derivative	LEUPRORELIN	2.08	2.47	4.52
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	1.18	1.85	3.89
Dysmenorrhea agent	FREWELL	-	1.01	2.01
GnRH antagonist	RELUMINA	-	0.87	1.98
Antihypertensive agent	AMLODIPINE	0.70	0.79	1.53
Hyperlipidemic agent	LIPDIL	1.12	0.78	1.21
Antithyroid agent	MERCAZOLE	0.60	0.70	1.34
Prostate cancer therapeutic agent	BICALUTAMIDE	0.62	0.69	1.06

*Including CANDESARTAN formulation's sales